Quarterly results for Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited – Q1 FY26 Results Summary
Announcement Date: 02 August 2025

Financial Performance (₹ Million):
- Consolidated:
- Revenue: ₹1,859.14 (+20% YoY, +11.2% QoQ)
- Net Profit: ₹404.40 (+15.6% YoY, +51.3% QoQ)
- Net Profit Margin: ~20.8%
- EPS (Basic & Diluted, not annualized): ₹3.57
- Standalone:
- Revenue: ₹1,250.24 (+45.5% YoY, +43.3% QoQ)
- Net Profit: ₹739.81 (+10.3% YoY, +569% QoQ)
- Net Profit Margin: ~41.3%
- EPS (Basic & Diluted, not annualized): ₹6.61

Other Income:
- Consolidated: ₹88.50 million
- Standalone: ₹538.52 million

Margins:
- Consolidated Operating Profit Margin (PBT): ~28.2%
- Standalone Operating Profit Margin (PBT): ~45.5%

Balance Sheet / Investments:
- ₹478.18 million invested in wholly owned subsidiary Advanced Enzymes Europe B.V. (Dec 2024)
- New wholly owned subsidiary Advanced Nutrazyme Private Limited incorporated (July 2025) for Nutrition & Wellness product sales and distribution
- Board approved up to ₹10 million further investment in Advanced Nutrazyme Private Limited by October 2025

Management Commentary:
- No changes in accounting policies or exceptional items reported
- Employee Stock Option Scheme (ESOP 2022) active with recent grants and share allotments
- Interim dividend of ₹4 per share paid in Q1 FY26; final dividend of ₹1.20 per share approved for FY25
- Financials of foreign subsidiaries reviewed and appropriately converted

Segment Performance:
- Single business segment: manufacturing and sales of enzymes
- Operations include subsidiaries in India, USA, Netherlands, Germany, and new entities

Key Developments:
- Incorporation of Advanced Nutrazyme Private Limited to expand into Nutrition & Wellness segment
- No impairments, restructuring, or disposals reported

Outlook:
- No explicit guidance provided for upcoming quarters

This summary reflects the key financial and operational highlights from Advanced Enzyme Technologies Limited’s Q1 FY26 results announcement.

Note: This is an AI generated summary of the results. There may be inaccuracies in the summary. Please refer to the original document before making investment decisions.